PD-1 blockade enhances elotuzumab efficacy in mouse tumor models Academic Article uri icon


  • Key Points The combination of elotuzumab and an anti–PD-1 antibody leads to enhanced antitumor efficacy in mouse models. Enhanced antitumor activity is likely due to the promotion of tumor-infiltrating NK and T-cell activity.


  • Bezman, Natalie A
  • Jhatakia, Amy
  • Kearney, Alper Y
  • Brender, Ty
  • Maurer, Mark
  • Henning, Karla
  • Jenkins, Misty R
  • Rogers, Amy J
  • Neeson, Paul J
  • Korman, Alan J
  • Robbins, Michael D
  • Graziano, Robert F

publication date

  • 2017